2CUREX AB (PUBL) Inactive Instrument
2cureX AB (publ) Stock Nasdaq Stockholm
Equities
SE0010468124
Biotechnology & Medical Research
| Sales 2021 | 7.39M 676K 924K | Sales 2022 | 3.37M 308K 421K | Capitalization | 143M 13.12M 17.94M |
|---|---|---|---|---|---|
| Net income 2021 | -18M -1.65M -2.25M | Net income 2022 | -29M -2.65M -3.63M | EV / Sales 2021 | 29.9 x |
| Net cash position 2021 | 72.94M 6.67M 9.12M | Net cash position 2022 | 44.89M 4.11M 5.62M | EV / Sales 2022 | 29.3 x |
| P/E ratio 2021 |
-14.6
x | P/E ratio 2022 |
-4.81
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on 2cureX AB (publ)
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 21-01-31 | |
Grith Hagel
FOU | Founder | 65 | 05-12-31 |
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ole Thastrup
FOU | Founder | 71 | 05-12-31 |
| Chairman | - | 11-13 |
2cureX AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of diagnostic substances to select treatment for cancer patients. The Company's product candidate, IndiTreat - CRC, aims at optimizing medical treatment for the colorectal cancer patients. Through IndiTreat - CRC, healthcare professionals collect a tumor sample from patients to create a number of three-dimensional micro tumors in order to test available chemotherapies and experimental treatments. The Company's product pipeline includes also IndiTreat - OVA, targeting ovarian cancer treatment, and IndiTreat - KDN, focusing on kidney cancer treatment. It operates through 2cureX A/S.
| 1st Jan change | Capi. | |
|---|---|---|
| -19.09% | 10.82B | |
| +48.03% | 3.25B | |
| -32.83% | 2.11B | |
| -17.21% | 2.08B | |
| -27.08% | 1.48B | |
| +20.38% | 1.02B | |
| -4.37% | 733M | |
| -34.25% | 391M | |
| -43.98% | 383M |
